Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy

  • Chenyu Liu
  • , Yang Li
  • , Zhihao Liu
  • , Chenxi Cao
  • , Min Lin
  • , Xin Chen
  • , Mengting Yuan
  • , Yaohua Fan
  • , Xiaodong Gu
  • , Lei Wang
  • , Fan Yang*
  • , Fei Ye*
  • , Jia Jin*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1) plays an important role in cell proliferation and gene expression, and is highly expressed in a variety of tumor tissues. Guided by our previous reported structure of DCPR049_12, we focused on designing and evaluating selective CARM1 inhibitors, resulting in the identification of compound 11f as a promising lead candidate. Compound 11f displayed potent inhibition of CARM1 (IC50 = 9 nM). Comprehensive evaluations, including in vitro metabolic stability assessments, molecular modelling, cellular studies, and in vivo anti-tumor studies, confirmed that it induced cancer cell apoptosis and specifically inhibited CARM1's methylation function. Notably, compound 11f displayed significant anti-proliferative effects on colorectal cancer cell lines, showcasing its potential for targeted therapies against CARM1-related diseases. This study provides valuable insights for the future development of specific and effective CARM1 inhibitors.

Original languageEnglish
Article number116288
JournalEuropean Journal of Medicinal Chemistry
Volume269
DOIs
StatePublished - 5 Apr 2024

Keywords

  • Antitumor
  • Arginine methyltransferase
  • Inhibitor
  • Methylate
  • PRMTs

Fingerprint

Dive into the research topics of 'Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy'. Together they form a unique fingerprint.

Cite this